Sumalatha Nandikonda
Rheumatology · Orlando, FLNPI 1174842017
Payments from drug & device makers
Across 250 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$895
- Amgen$483
- GSK$356
- Boehringer Ingelheim$221
- UCB, Inc.$192
- plus $1K from 14 others
What the payments were for
- Food & beverage$4,38798%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 62 | $1,123 |
| AbbVie | 55 | $895 |
| Amgen(2 entities) | 26 | $483 |
| GSK | 24 | $356 |
| Boehringer Ingelheim | 9 | $221 |
| UCB, Inc. | 11 | $192 |
| Pfizer | 12 | $178 |
| E.r. Squibb & Sons, L.L.C. | 11 | $172 |
| Janssen Scientific Affairs, LLC | 1 | $146 |
| AstraZeneca | 6 | $130 |
| Novartis | 7 | $129 |
| Mallinckrodt Hospital Products Inc. | 7 | $126 |
| Lilly USA, LLC | 7 | $93 |
| Genentech USA, Inc. | 6 | $85 |
| Radius Health, Inc. | 1 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Sobi, Inc | 1 | $21 |
| Invivyd Inc | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Mylan Institutional Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$146
How this compares
$4,462 in reported general payments places this provider in the 40th percentile of 453 rheumatology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orencia ClickjectAbatacept | 14 | $89,786 |
| Enbrel SureclickEtanercept | 12 | $84,878 |
| OrenciaAbatacept/Maltose | 12 | $54,708 |
| Hydroxychloroquine Sulfate | 58 | $3,276 |
| Leflunomide | 14 | $917 |
| MethotrexateMethotrexate Sodium | 47 | $888 |
| Celecoxib | 13 | $620 |
| Prednisone | 75 | $554 |
| Duloxetine Hcl | 20 | $451 |
| Gabapentin | 15 | $199 |
| Allopurinol | 12 | $165 |
| Meloxicam | 15 | $67 |
| Pantoprazole Sodium | 12 | $40 |
| Sodium Chloride0.9 % Sodium Chloride | 12 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Orencia | $172 | $54,70812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Orlando
- Martha Hernandez IllasFort Lauderdale$25M
- Carlos SesinMiami Beach$19M
- Guillermo ValenzuelaPlantation$14.2M
- Marimer Rensoli VelazquezMiami$12.2M
- Robert LevinClearwater$11M
- Jigar ShahMargate$5.6M
- Michael BubbGainesville$3.3M
- Vipul JoshiBrandon$3.1M
- Alvin WellsDestin$2.9M
- Benidecto FernandezHialeah$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.